Highly potent active pharmaceutical ingredients (HPAPIs) are increasingly becoming mainstream, moving beyond their traditional association with oncology products. A recent report by Grand View Research indicates that the global HPAPI market was valued at $29.9 billion in 2025, with projections to reach $48.3 billion by 2033, driven by the rising prevalence of cancer and the adoption of targeted therapies.
As the drug development landscape shifts towards more targeted therapies, the complexity of handling HPAPIs is escalating. This evolution requires contract development and manufacturing organizations (CDMOs) to enhance their capabilities to meet the growing demand for specialized containment and safety measures. The need for robust containment strategies is now paramount, as sponsors expect comprehensive risk assessments and verification processes to ensure safe handling of these potent compounds.
This editorial delves into the evolving HPAPI manufacturing landscape, highlighting the implications for CDMOs and pharmaceutical companies. It emphasizes the importance of early collaboration, flexible manufacturing processes, and the integration of advanced technologies to meet the challenges posed by increasingly potent and diverse drug pipelines.
Get started today with Solo access →
